Search Results for "Ondansetron Im"

03:27 EDT 16th September 2014 | BioPortfolio

Original Source: ONDANSETRON [Ranbaxy Pharmaceuticals Inc.]

Matching Channels


Matching News

Newman's Notes: Inside the Ondansetron Black Box (CME/CE)

(MedPage Today) -- Emergency physician David H. Newman, MD, dissects the ondansetron black box warning.

Ondansetron, Metoclopramide Similar in Head-to-Head Trial

Ondansetron is more expensive but no better than metoclopramide in treating morning sickness in pregnant women; women taking metoclopramide reported more minor adverse effects. Medscape Medical News

MonosolRx finds new licensee for oral film delivered ondansetron

MonosolRx has found a new US licensee for its oral film ondansetron product, Zuplenz, signing up Galena BioPharma nearly four years after previous partner Strativa handed the drug back.

Galena Biopharma Enters Into Definitive Agreement to License U.S. Rights for Zuplenz(R) (ondansetron) Oral Soluble Film

Novel, rapidly dissolving oral PharmFilm® enables faster absorption, increased convenience and better compliance for patients. Planned launch in multiple indications—chemotherapy-, radiat...

RedHill begins Phase III RHB-102 trial to treat gastroenteritis

RedHill Biopharma has initiated a Phase III clinical trial of RHB-102, an oral, extended-release, once-daily formulation of the antiemetic drug ondansetron, to treat patients suffering from acute gast...

Galena Biopharma licenses US rights to MonoSol Rx's Zuplenz

Galena Biopharma Inc. (oncology) licensed exclusive US rights to drug delivery firm MonoSol Rx LLC’s Zuplenz, a marketed oral ondansetron film product for nausea and vomiting related to chemotherapy...

RedHill gets FDA approval to start Phase III trial of RHB-102

Israeli biopharmaceutical firm RedHill Biopharma has received approval from the US Food and Drug Administration (FDA) to start its planned Phase III clinical trial for the treatment of a new, undisclo...

Galena Biopharma inks licensing deal with MonoSol Rx for US rights of Zuplenz

US-based biopharmaceutical firm Galena Biopharma has entered into a definitive agreement to license the US rights for Zuplenz (ondansetron) oral soluble film (OSF), from MonoSol Rx, the developer of t...

Matching PubMed Articles

Effect of adding 8 milligrams ondansetron to lidocaine for Bier's block on post-operative pain.

Ondansetron has analgesic properties. The aim of the present study was to assess the analgesic effect of 8 mg ondansetron when added to lidocaine for intravenous regional anesthesia (IVRA).

Off-label use of ondansetron in pregnancy in Western australia.

Aims. Nausea and vomiting of pregnancy is the most common medical condition in pregnancy. There is an increasing trend to prescribe ondansetron although its safety for use in pregnancy has not been es...

Prevention versus treatment of intrathecal morphine-induced pruritus with ondansetron.

Intrathecal morphine is used for post-cesarean analgesia, but pruritus is a common side effect. Ondansetron would be an attractive treatment because it prevents nausea, is non-sedative or has no anti-...

Integration of Modeling and Simulation to Support Changes to Ondansetron Dosing Following A Randomized, Double-Blind, Placebo-, and Active-Controlled Thorough QT Study.

Prolongation of the QT interval has been observed with ondansetron and other members of the 5-HT3 antagonist class. This is the first thorough QTc study of ondansetron conducted in accordance with ICH...

Ondansetron reducing pain on injection of etomidate: a controlled randomized study.

Etomidate causes pain when injected intravenously. In this study we sought to determine if pretreatment by ondansetron reduces the pain on injection of etomidate.

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement